Acute Kidney InjuryMARCENCT02332070
Timing of Coronary Angiography, Cardiac Surgery, and Adverse Renal and Cardiac Events (MARCE)
An observational study of Acute Kidney Injury and Renal Insufficiency, run by Baylor Research Institute at 1 site in United States.
Trial summary
1. To examine two main predictor variables independently and then jointly in stratified and multivariate analyses for the outcomes of CSA-AKI, MARCE, need for RRT, and inpatient mortality, and the composite, as well as the outcomes of 30 day rehospitalization or death, and finally for the days out of hospital and… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Acute Kidney Injury, Renal Insufficiency
- What is being tested?
- cardiac surgery
- Type of treatment
- Surgery or procedure
- How many people
- 965 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2015to Feb 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Using the Texas Quality Initiative cardiothoracic surgery database, patients who have recorded one preoperative and at least one baseline and postoperative serum creatinine (mg/dl).
Who may be able to join
- Cardiac surgery with or without cardiac valve surgery
- At least one baseline and postoperative serum creatinine (mg/dl)
Who cannot join
- Use of contrast agent other than IOCM with the preoperative angiogram
- Preoperative use of ventricular assist devices and intraaortic balloon counterpulsation.
- Operations where there is implantation of mechanical assist devices or cardiac transplant
Trial locations and contacts
1 site in 1 country.
United States1 site
Baylor Heart and Vascular Institute
Dallas, Texas, 75226
About this study
Official title: Timing of Coronary Angiography and Multivariate Risk for Cardiac Surgery Associated Acute Kidney Injury and Major Adverse Renal and Cardiac Events (MARCE)
- To examine two main predictor variables independently and then jointly in stratified and multivariate analyses for the outcomes of CSA-AKI, MARCE, need for RRT, and inpatient mortality, and the composite, as well as the outcomes of 30 day rehospitalization or death, and finally for the days out of hospital and alive adjusted to person-year of time
- Days from coronary angiogram performed with IOCM to cardiac surgery (1, 2, 3, etc)
- Thakar Acute Renal Failure (ARF) score (1 to 17)
- To examine the interrelationships between time in days between angiogram and surgery and the ARF Score with the Society of Thoracic Surgery (STS) Risk score for mortality
Read the detailed description
Background: Despite advances in cardiac surgical techniques, modern anesthesia, and adjunctive medical therapies, cardiac-surgery associated acute kidney injury (CSA-AKI) remains a frequent and important complication. With advancing age and more severe comorbidities present in patients undergoing cardiac surgery, multivariate scores (e.g. Thakar Acute Renal Failure [ARF] score) would anticipate future higher rates of CSA-AKI that resolve, lead to progressive chronic kidney disease (CKD), require renal replacement therapy (RRT), and are associated major adverse cardiac events with early and later mortality. Mehta and colleagues in a study of 2441 cases suggested that CSA-AKI was associated with the time between the diagnostic coronary angiogram and the subsequent surgery. This suggested that superimposed risk of contrast-induced AKI (CI-AKI) followed by cardiac surgery was a serial insult to the kidneys producing the clinical syndrome of CSA-AKI. However, Andersen and coworkers, in a study of 285 consecutive patients concluded that cardiac surgery within 1-3 days of coronary angiography was safe and not associated with CSA-AKI. Attempts at evaluating CSA-AKI risk prediction models have been limited by small sample sizes. For example, Kiers et el attempted to evaluate 8 CSA-AKI risk models in 1388 patients and found several scores could not be computed due to lack of information and those that could have unstable point estimates for C-statistics and other measures. As a result, CSA-AKI risk scores and attempts to improve quality of care have not been applied in a widespread manner to cardiac surgical cases. Thus we propose to evaluate these key concepts in a large dataset which captures important clinical events such as CI-AKI and type of contrast used followed by CSA-AKI and associated major adverse renal and cardiac events (MARCE) including the need for RRT, myocardial infarction, stroke, heart failure, hospitalizations (cardiac or renal) and death. We aim to derive a practical approach in determining the optimal waiting period from the time of angiography to cardiac surgery according to risk for CSA-AKI in subjects who have received iso-osmolar contrast media (IOCM) with preoperative angiography, as that agent has been shown to have the lowest risk of CI-AKI.
Specific Aims:
- To examine two main predictor variables independently and then jointly in stratified and multivariate analyses for the outcomes of CSA-AKI, MARCE, need for RRT, and inpatient mortality, and the composite, as well as the outcomes of 30 day rehospitalization or death, and finally for the days out of hospital and alive adjusted to person-year of time
- Days from coronary angiogram performed with IOCM to cardiac surgery (1, 2, 3, etc)
- Thakar Acute Renal Failure (ARF) score (1 to 17)
- To examine the interrelationships between time in days between angiogram and surgery and the ARF Score with the Society of Thoracic Surgery (STS) Risk score for mortality
Methods
Study Design: Retrospective cohort
Subjects: Using the Texas Quality Initiative cardiothoracic surgery database, patients who have recorded one preoperative and at least one postoperative serum creatinine (mg/dl).
Excluded Cases
- Use of contrast agent other than IOCM with the preoperative angiogram
- Preoperative use of ventricular assist devices and intraaortic balloon counterpulsation.
- Operations where there is implantation of mechanical assist devices or cardiac transplant
Measurements:
- CI-AKI will be assessed by several methods during the period from angiography to cardiac surgery:
- Kidney Disease International Global Initiative (KDIGO) as a rise in serum creatinine ≥0.3 mg/dl within 48 hours of surgery or ≥1.5 X baseline serum creatinine within seven days after surgery
- Conventional composite CI-AKI definition of ≥25% or ≥0.5 mg/dl rise in serum creatinine from baseline to peak
- Conventional singular CI-AKI definition of ≥25% rise in serum creatinine from baseline to peak
- Conventional singular CI-AKI definition of ≥0.5 mg/dl rise in serum creatinine from baseline to peak
- CSA-AKI will be defined by several methods:
- Kidney Disease International Global Initiative (KDIGO) as a rise in serum creatinine ≥0.3 mg/dl within 48 hours of surgery or ≥1.5 X baseline serum creatinine within seven days after surgery
- Conventional composite derived from CI-AKI definition of ≥25% or ≥0.5 mg/dl rise in serum creatinine from baseline to peak
- Conventional singular derived from CI-AKI definition of ≥25% rise in serum creatinine from baseline to peak
- Conventional singular derived from CI-AKI definition of ≥0.5 mg/dl rise in serum creatinine from baseline to peak
- MARCE will be the composite of RRT, myocardial infarction, stroke, heart failure, hospitalizations for cardiac reasons, hospitalization for renal reasons, and death
- RRT will include at least one session of peritoneal dialysis ultrafiltration, hemodialysis, or other form of extracorporeal blood purification
- All-cause hospitalization, emergency room, and observation unit visits at 30 days, and one-year will be obtained from the Dallas-Fort Worth Hospital Council Education and Research (DFWHC) connected a regional enterprise master person index (REMPI) database
- All-cause mortality will be reported as inpatient, 30-day, and one-year
- Days out of the hospital and alive will be derived as the converse of death and hospitalized days and will be adjusted to 100 PY of time exposure
- Baseline eGFR will be calculated using the CKD-EPI formula GFR = 141 X min(Scr/κ,1)α X max(Scr/κ,1)-1.209 X 0.993Age X 1.018 [if female] X 1.159 [if black] Where Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1.
- Clinical factors: age, diabetes, Hb, heart failure, operative variables (bypass time, coronary bypass with valve surgery, on-pump, off-pump) and other predictors of CSA-AKI will be reported in baseline characteristics and considered as candidates for multivariable models
- Conditions
- Acute Kidney Injury, Renal Insufficiency
- Being tested
- cardiac surgery
- Keywords
- acute kidney injury, coronary angiography, cardiac surgery, adverse events, iodinated contrast, Thoracic Surgery
- Medical subject headings
- Acute Kidney Injury, Renal Insufficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
cardiac surgeryProcedure or surgery
coronary artery bypass surgery and or cardiac valve surgery with cardiopulmonary bypass
What is being measured
The primary outcome is the main question the study is designed to answer.
Contrast-induced acute kidney injury
KDIGO definition
Measured: 7 days
Cardiac surgery associated acute kidney injury
KDIGO definition
Measured: 7 days
Major adverse renal and cardiac events
Composite of need for renal replacement therapy, myocardial infarction, stroke, heart failure, hospitalizations for cardiac reasons, hospitalization for renal reasons, and death
Measured: 30 days
Secondary outcomes (9)
Renal replacement therapy
at least one session of peritoneal dialysis ultrafiltration, hemodialysis, or other form of extracorporeal blood purification
Measured: 30 days
Myocardial Infarction
Myocardial infarction as defined by STS
Measured: 30 days
Stroke
Stroke as defined by STS
Measured: 30 days
Heart failure
Heart failure
Measured: 30 days
Hospitalization for renal reasons
Hospitalization for renal reasons
Measured: 30 days
Hospitalization for cardiac reasons
Hospitalization for cardiac reaons
Measured: 30 days
Death
Death
Measured: 30 days
All-cause hospitalization
All-cause hospitalization, emergency room, and observation unit visits at 30 days, and one-year will be obtained from the Dallas-Fort Worth Hospital Council Education and Research (DFWHC) connected a regional enterprise master person index (REMPI) database
Measured: 30 days
Days out of the hospital and alive
Days out of the hospital and alive will be derived as the converse of death and hospitalized days and will be adjusted to 100 PY of time exposure
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jan 2015 (estimated)
- Study startJan 2015
- Primary completionFeb 2017
- Study completionFeb 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Acute Kidney InjuryStudies of the same condition, open and under way.
- More trials run by Baylor Research InstituteThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 965 participants (actual)
Sponsor and investigators
- Lead sponsor
- Baylor Research Institute
- Sponsor type
- University, hospital or other
- Collaborators
- GE Healthcare
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02332070
- Sponsor's protocol ID
- 014-096
- Acronym
- MARCE
- Status last verified
- Feb 2018
- First submitted
- 5 Jan 2015
- Last updated
- 12 Feb 2018
- Results posted
- No
- Data monitoring committee
- No
Publications
McCullough PA, Brown JR. Effects of Intra-Arterial and Intravenous Iso-Osmolar Contrast Medium (Iodixanol) on the Risk of Contrast-Induced Acute Kidney Injury: A Meta-Analysis. Cardiorenal Med. 2011;1(4):220-234. doi: 10.1159/000332384. Epub 2011 Oct 4.
PubMed 22164156Chawla LS, Amdur RL, Shaw AD, Faselis C, Palant CE, Kimmel PL. Association between AKI and long-term renal and cardiovascular outcomes in United States veterans. Clin J Am Soc Nephrol. 2014 Mar;9(3):448-56. doi: 10.2215/CJN.02440213. Epub 2013 Dec 5.
PubMed 24311708Tecson KM, Brown D, Choi JW, Feghali G, Gonzalez-Stawinski GV, Hamman BL, Hebeler R, Lander SR, Lima B, Potluri S, Schussler JM, Stoler RC, Velasco C, McCullough PA. Major Adverse Renal and Cardiac Events After Coronary Angiography and Cardiac Surgery. Ann Thorac Surg. 2018 Jun;105(6):1724-1730. doi: 10.1016/j.athoracsur.2018.01.010. Epub 2018 Feb 2.
PubMed 29408241
Study at a glance
From the registry record, last updated by the sponsor on 12 Feb 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Timing of Coronary Angiography and Multivariate Risk for Cardiac Surgery Associated Acute Kidney Injury and Major Adverse Renal and Cardiac Events (MARCE)
- ClinicalTrials.gov ID
- NCT02332070
- Acronym / sponsor ID
- MARCE / 014-096
- Conditions
- Acute Kidney Injury, Renal Insufficiency
- Keywords
- acute kidney injury, coronary angiography, cardiac surgery, adverse events, iodinated contrast, Thoracic Surgery
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 965 participants (actual)
- Lead sponsor
- Baylor Research InstituteUniversity, hospital or other
- Collaborators
- GE Healthcare
- Study start
- Jan 2015
- Primary completion
- Feb 2017 (actual)
- Study completion
- Feb 2018 (actual)
- First posted
- 6 Jan 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- To examine two main predictor variables independently and then jointly in stratified and multivariate analyses for the outcomes of CSA-AKI, MARCE, need for RRT, and inpatient mortality, and the composite, as well as the outcomes of 30 day rehospitalization or death, and finally for the days out of hospital and alive adjusted to person-year of time
- Days from coronary angiogram performed with IOCM to cardiac surgery (1, 2, 3, etc)
- Thakar Acute Renal Failure (ARF) score (1 to 17)
- To examine the interrelationships between time in days between angiogram and surgery and the ARF Score with the Society of Thoracic Surgery (STS) Risk score for mortality
Detailed description
Background: Despite advances in cardiac surgical techniques, modern anesthesia, and adjunctive medical therapies, cardiac-surgery associated acute kidney injury (CSA-AKI) remains a frequent and important complication. With advancing age and more severe comorbidities present in patients undergoing cardiac surgery, multivariate scores (e.g. Thakar Acute Renal Failure [ARF] score) would anticipate future higher rates of CSA-AKI that resolve, lead to progressive chronic kidney disease (CKD), require renal replacement therapy (RRT), and are associated major adverse cardiac events with early and later mortality. Mehta and colleagues in a study of 2441 cases suggested that CSA-AKI was associated with the time between the diagnostic coronary angiogram and the subsequent surgery. This suggested that superimposed risk of contrast-induced AKI (CI-AKI) followed by cardiac surgery was a serial insult to the kidneys producing the clinical syndrome of CSA-AKI. However, Andersen and coworkers, in a study of 285 consecutive patients concluded that cardiac surgery within 1-3 days of coronary angiography was safe and not associated with CSA-AKI. Attempts at evaluating CSA-AKI risk prediction models have been limited by small sample sizes. For example, Kiers et el attempted to evaluate 8 CSA-AKI risk models in 1388 patients and found several scores could not be computed due to lack of information and those that could have unstable point estimates for C-statistics and other measures. As a result, CSA-AKI risk scores and attempts to improve quality of care have not been applied in a widespread manner to cardiac surgical cases. Thus we propose to evaluate these key concepts in a large dataset which captures important clinical events such as CI-AKI and type of contrast used followed by CSA-AKI and associated major adverse renal and cardiac events (MARCE) including the need for RRT, myocardial infarction, stroke, heart failure, hospitalizations (cardiac or renal) and death. We aim to derive a practical approach in determining the optimal waiting period from the time of angiography to cardiac surgery according to risk for CSA-AKI in subjects who have received iso-osmolar contrast media (IOCM) with preoperative angiography, as that agent has been shown to have the lowest risk of CI-AKI.
Specific Aims:
- To examine two main predictor variables independently and then jointly in stratified and multivariate analyses for the outcomes of CSA-AKI, MARCE, need for RRT, and inpatient mortality, and the composite, as well as the outcomes of 30 day rehospitalization or death, and finally for the days out of hospital and alive adjusted to person-year of time
- Days from coronary angiogram performed with IOCM to cardiac surgery (1, 2, 3, etc)
- Thakar Acute Renal Failure (ARF) score (1 to 17)
- To examine the interrelationships between time in days between angiogram and surgery and the ARF Score with the Society of Thoracic Surgery (STS) Risk score for mortality
Methods
Study Design: Retrospective cohort
Subjects: Using the Texas Quality Initiative cardiothoracic surgery database, patients who have recorded one preoperative and at least one postoperative serum creatinine (mg/dl).
Excluded Cases
- Use of contrast agent other than IOCM with the preoperative angiogram
- Preoperative use of ventricular assist devices and intraaortic balloon counterpulsation.
- Operations where there is implantation of mechanical assist devices or cardiac transplant
Measurements:
- CI-AKI will be assessed by several methods during the period from angiography to cardiac surgery:
- Kidney Disease International Global Initiative (KDIGO) as a rise in serum creatinine ≥0.3 mg/dl within 48 hours of surgery or ≥1.5 X baseline serum creatinine within seven days after surgery
- Conventional composite CI-AKI definition of ≥25% or ≥0.5 mg/dl rise in serum creatinine from baseline to peak
- Conventional singular CI-AKI definition of ≥25% rise in serum creatinine from baseline to peak
- Conventional singular CI-AKI definition of ≥0.5 mg/dl rise in serum creatinine from baseline to peak
- CSA-AKI will be defined by several methods:
- Kidney Disease International Global Initiative (KDIGO) as a rise in serum creatinine ≥0.3 mg/dl within 48 hours of surgery or ≥1.5 X baseline serum creatinine within seven days after surgery
- Conventional composite derived from CI-AKI definition of ≥25% or ≥0.5 mg/dl rise in serum creatinine from baseline to peak
- Conventional singular derived from CI-AKI definition of ≥25% rise in serum creatinine from baseline to peak
- Conventional singular derived from CI-AKI definition of ≥0.5 mg/dl rise in serum creatinine from baseline to peak
- MARCE will be the composite of RRT, myocardial infarction, stroke, heart failure, hospitalizations for cardiac reasons, hospitalization for renal reasons, and death
- RRT will include at least one session of peritoneal dialysis ultrafiltration, hemodialysis, or other form of extracorporeal blood purification
- All-cause hospitalization, emergency room, and observation unit visits at 30 days, and one-year will be obtained from the Dallas-Fort Worth Hospital Council Education and Research (DFWHC) connected a regional enterprise master person index (REMPI) database
- All-cause mortality will be reported as inpatient, 30-day, and one-year
- Days out of the hospital and alive will be derived as the converse of death and hospitalized days and will be adjusted to 100 PY of time exposure
- Baseline eGFR will be calculated using the CKD-EPI formula GFR = 141 X min(Scr/κ,1)α X max(Scr/κ,1)-1.209 X 0.993Age X 1.018 [if female] X 1.159 [if black] Where Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1.
- Clinical factors: age, diabetes, Hb, heart failure, operative variables (bypass time, coronary bypass with valve surgery, on-pump, off-pump) and other predictors of CSA-AKI will be reported in baseline characteristics and considered as candidates for multivariable models
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Using the Texas Quality Initiative cardiothoracic surgery database, patients who have recorded one preoperative and at least one baseline and postoperative serum creatinine (mg/dl).
Key inclusion criteria (2 listed)
- Cardiac surgery with or without cardiac valve surgery
- At least one baseline and postoperative serum creatinine (mg/dl)
Key exclusion criteria (3 listed)
- Use of contrast agent other than IOCM with the preoperative angiogram
- Preoperative use of ventricular assist devices and intraaortic balloon counterpulsation.
- Operations where there is implantation of mechanical assist devices or cardiac transplant
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| cardiac surgerycoronary artery bypass surgery and or cardiac valve surgery with cardiopulmonary bypass | Procedure or surgery | – |
Primary outcome
Contrast-induced acute kidney injury
Time frame: 7 days
KDIGO definition
Cardiac surgery associated acute kidney injury
Time frame: 7 days
KDIGO definition
Major adverse renal and cardiac events
Time frame: 30 days
Composite of need for renal replacement therapy, myocardial infarction, stroke, heart failure, hospitalizations for cardiac reasons, hospitalization for renal reasons, and death
9 secondary outcomes
Renal replacement therapy
Time frame: 30 days
Myocardial Infarction
Time frame: 30 days
Stroke
Time frame: 30 days
Heart failure
Time frame: 30 days
Hospitalization for renal reasons
Time frame: 30 days
Hospitalization for cardiac reasons
Time frame: 30 days
Death
Time frame: 30 days
All-cause hospitalization
Time frame: 30 days
Days out of the hospital and alive
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Feb 2018.
- Background: PubMed 22164156McCullough PA, Brown JR. Effects of Intra-Arterial and Intravenous Iso-Osmolar Contrast Medium (Iodixanol) on the Risk of Contrast-Induced Acute Kidney Injury: A Meta-Analysis. Cardiorenal Med. 2011;1(4):220-234. doi: 10.1159/000332384. Epub 2011 Oct 4.
- Background: PubMed 24311708Chawla LS, Amdur RL, Shaw AD, Faselis C, Palant CE, Kimmel PL. Association between AKI and long-term renal and cardiovascular outcomes in United States veterans. Clin J Am Soc Nephrol. 2014 Mar;9(3):448-56. doi: 10.2215/CJN.02440213. Epub 2013 Dec 5.
- Results publication: PubMed 29408241Tecson KM, Brown D, Choi JW, Feghali G, Gonzalez-Stawinski GV, Hamman BL, Hebeler R, Lander SR, Lima B, Potluri S, Schussler JM, Stoler RC, Velasco C, McCullough PA. Major Adverse Renal and Cardiac Events After Coronary Angiography and Cardiac Surgery. Ann Thorac Surg. 2018 Jun;105(6):1724-1730. doi: 10.1016/j.athoracsur.2018.01.010. Epub 2018 Feb 2.
Related trials for Acute Kidney Injury
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruiting
Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery
Renal Injury, Acute Kidney Injury
Recruiting
Acute Kidney Injury and Ultra-endurance Running
AKI (Acute Kidney Injury) Due to Trauma
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Not yet recruitingObservational study
Diastolic Shock Index for Predicting Hemodynamic Instability During Continuous Renal Replacement Therapy
Acute Kidney Injury, Hypotension (MeSH: D007022)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Kidney Injury and Renal Insufficiency, run by Baylor Research Institute at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Feb 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Contrast-induced acute kidney injury (time frame: 7 days). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02332070, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Feb 2018.